Pharmaceuticals

An ambitious challenge aims to turn Amazon biodiversity into sustainable businesses, betting that entrepreneurship is the key to the rainforest's survival.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Wellcome and Nature launch the world's largest mental health prize, aiming to spark a revolution in a field plagued by underfunding and access gaps.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

OrganaBio's strategic acquisition of Excellos creates a coast-to-coast manufacturing entity, aiming to de-risk and accelerate the complex cell therapy supply chain.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

ICON plc opens a state-of-the-art San Antonio research unit, aiming to accelerate drug development and improve the patient trial experience.

Benchling launches Model Hub, an integrated platform to democratize AI in biotech, aiming to slash R&D timelines by embedding models into daily workflows.

Private equity firm Thurston Group launches Sensorium Clinical Research, a new network aiming to unify top trial sites and streamline medical innovation.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

The 2026 Giants of Multiple Sclerosis® awards celebrate the multidisciplinary teams shaping the future of MS, from research to rehabilitation.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.